Future experiments involving enzyme inhibition or modifications of downstream targets in samples from the treated mouse should provide a key causal link between in vivo/preclinical DYRK1A inhibition and the behavioral effects of PST-001 in this mouse model of DS. The gene discussed is DYRK1A; the disease is Dravet syndrome.